Get Adobe Flash player

Avista Capital Companions to obtain Bristol-Myers Squibb Medical Imaging for $525 Million Bristol-Myers Squibb Organization and Avista Capital Partners, a respected private equity company, announced today the celebrations have got signed a definitive contract for Avista to obtain Bristol-Myers Squibb Medical Imaging , a continuing business device of Bristol-Myers Squibb, for about $525 million of money proceeds. BMS MI can be a leading provider of medical imaging items for nuclear and ultrasound cardiovascular diagnostic imaging techniques tadapox tablets click here . As Bristol-Myers Squibb proceeds to spotlight evolving right into a next-era BioPharma organization, we determined the simplest way to maximize the worthiness of Medical Imaging for shareholders was to market this business and reinvest the proceeds into our pharmaceutical study, commercialization and development attempts, stated James M. Cornelius, ceo, Bristol-Myers Squibb. Simultaneously, we think that Medical Imaging can increase its potential under fresh ownership, and Avista includes a proven history of achievement in the health care field. David Burgstahler, somebody at Avista Capital Companions, said, Bristol-Myers Squibb Medical Imaging is certainly more popular as a pioneer in cardiovascular imaging brokers, and because of its strong specialized manufacturing experience. BMS MI is a superb fit for our health care portfolio, since it addresses the health care industry’s increasing dependence on improved diagnostic tools. We believe that it is well-positioned for continued achievement. The transaction is likely to be completed by the finish of January 2008, at the mercy of customary regulatory approvals, of which period BMS MI shall operate as an unbiased company under a fresh name. Don Kiepert, the founder and previous Chairman, CEO, and President of Point Therapeutics, can be the principle executive officer of the business upon completion of the deal. I am thrilled to end up being partnering with the prevailing management group of BMS MI and Avista Capital once we changeover BMS MI to an unbiased company, stated Kiepert. BMS MI provides exceptional brands, a cutting-edge advancement and research facility, and a educated sales team. It is an excellent fit for our health care portfolio, since it addresses the health care industry’s increasing dependence on improved diagnostic equipment, stated Larry Pickering, Avista Capital Companions’ healthcare sector partner. We think that BMS MI can be well-positioned for continued achievement and Don Kiepert may be the right head to optimize the development possibilities within BMS MI’s pipeline. Tim Ravenscroft, president of BMS MI stated, The Avista team is usually focused on long-term growth, so when the brand new owner of the business enterprise, will renew our concentrate on expanding and developing our business. Bristol-Myers Squibb Medical Imaging will end up being Avista’s 6th investment in the health care industry. On 13 December, 2007, Avista decided to acquire from Boston Scientific its Fluid Administration and Venous Gain access to businesses. In 2007 Also, Avista made health care investments in BioReliance ( and VWR International ( and in 2006 Avista announced investments in Nycomed ( and MedServe ( While at DLJ Merchant Banking Companions, the Avista companions were involved with numerous health care transactions including Accellent, Charles River Laboratories, Concentrate Diagnostics, KCI, NextPharma, Prometheus Labs, and Warner Chilcott. J.P. Morgan Securities Inc. Served as economic advisor for Bristol-Myers Squibb and Cravath, Swaine & Moore LLP offered as lawyer for the company. Weil, Gotshal & Manges offered as lawyer for Avista Capital Companions. About Bristol-Myers Squibb and Bristol-Myers Squibb Medical Imaging Bristol-Myers Squibb Organization is a worldwide biopharmaceutical and related healthcare products organization. Bristol-Myers Squibb Medical Imaging is definitely a worldwide innovator in cardiovascular imaging. Bristol-Myers Squibb Medical Imaging is normally a subsidiary of Bristol-Myers Squibb Company. To find out more, visit About Avista Capital Companions Avista Capital Companions is a respected private equity company with offices in NY, Houston and NY, TX. Founded in 2005, Avista’s strategy would be to make managing or influential minority investments mainly in growth-oriented media, energy and healthcare companies. Through its group of seasoned investment experts and industry experts, Avista seeks to partner with outstanding management teams to purchase and add worth to well-positioned businesses. To learn more, visit.

Avedro receives Canadian authorization for KXL II System Avedro Inc., a Boston-based ophthalmic medical gadget and pharmaceutical business announces today the Canadian acceptance for the company's KXL II Program. The KXL II gadget is made to deliver particular light patterns to the cornea in line with the individual's have topographic data that is collected during program pre-operative screening. This enables cross-linking to be personalized to a individual's particular refractive requirements. Related StoriesLaser eye medical procedures: a glimpse in to the long term – An interview with Professor Dan ReinsteinOmeros reviews extra positive data from OMS721 Stage 2 trial for treatment of thrombotic microangiopathiesImprimis, Advanced Dosage indication license contract for proprietary compounded ophthalmic formulations Avedro has recently begun installing its brand-new KXL II gadget in multiple sites all over the world. Early clinical outcomes, with follow-up approaching twelve months, will be talked about at the forthcoming '3rd International Congress about Advanced Corneal Cross-Linking' becoming held with the AECOS European Interacting with on June 28th, 2014. David Muller, PhD, CEO of Avedro claims, ‘With this authorization of the KXL II, Canada joins the 28 members of europe which have received the CE tag and approval to utilize this advanced technology. This groundbreaking procedure for dealing with myopia and astigmatism gets the potential to start refractive correction to thousands of people who’ve never considered LASIK medical procedures before, but would look at a nonsurgical alternative. Furthermore, it gets the potential to improve the outcome of routine cataract methods by non-surgically reducing post-operative astigmatism.

Random articles
Other articles from "manual therapy":